Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform

Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug ClassesMELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product. In a comparative pharmacokinetic stu ...